ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Cartesian Initiates Trial of Cell Therapy for ARDS, COVID-19 americanpharmaceuticalreview
September 02, 2020Cartesian Therapeutics has initiated a Phase 1/2 clinical trial of its lead RNA-engineered mesenchymal stem cell (MSC) therapy, Descartes-30, in patients with moderate-to-severe acute respiratory distress syndrome (ARDS), including that caused by COVID-19
Pharma Sources Insight July 2025
